Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham ADHD Stimulant PA | OpenPayer
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Attention Deficit Hyperactivity Disorder (ADHD) Stimulants Step Therapy

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs commercial/Exchange pharmacy-benefit coverage for stimulant medications used primarily to treat attention-deficit/hyperactivity disorder. First-line agents are available without prior authorization, while second-line agents require specified prior use, clinical exception criteria, or documentation for members who are new to the plan.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyAttention Deficit Hyperactivity Disorder (ADHD) Stimulants Step Therapy
    Policy CodePolicy N/A
    Change TypeMaterial update
    Effective DateJan 1, 202743d
    Last ReviewSep 9, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request when a second-line prescription does not meet the initial step-therapy requirement at the point of sale.
    SourceLink
    POLICY UPDATE CHANGES

    Quillichew ER was removed from the policy because it is moving to nonformulary status.

    Generic Mydayis was added to the step-therapy program.

    The policy added criteria for members who are new to the plan.

    Quantity limits were added to the policy.

    Approval criteria were updated to allow lisdexamfetamine capsules for binge-eating disorder.

    5

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    first-line stimulant products or product forms
    5second-line stimulant products or product forms
    180 dayslookback period for qualifying pharmacy fills
    12 monthsmaximum approval duration
    12drug and dosage-form quantity-limit entries

    Coverage Criteria

    Second-line clinical exception

    Authorization may be granted when all of the following criteria are met.

    Clinical exception pathway

    • Qualifying clinical pathway

      • First-line intolerance or failure: The member has had a trial and failure, adverse reaction, or contraindication to at least two first-line long-acting stimulants.at least 2 first-line long-acting stimulants
      • Second-line failure: The member has had a trial and failure with at least one second-line long-acting stimulant.at least 1 second-line long-acting stimulant
      • Binge-eating disorder pathway: The request is for a lisdexamfetamine capsule and the member has a diagnosis of binge-eating disorder.

    New-plan member coverage

    A separate pathway applies to members who are new to the plan.

    New-plan member pathway: The member's coverage effective date is less than or equal to 90 days, and medical records document that the member is currently receiving treatment with the requested drug.coverage effective date <= 90 days

    Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify as evidence for this pathway.

    Treatment with the requested drug obtained as samples or through a manufacturer’s patient assistance program does not qualify as evidence for the new-plan member coverage pathway.

    Provider and Claim Actions

    Prior Authorization

    Prior Authorization Required When Initial Step Is Not Met

    Prescriptions that meet the initial step-therapy requirements adjudicate automatically at the point of sale. If the requirements are not met, the prescription will deny with a message that prior authorization (PA) is required; submit a PA request for members who do not meet the initial step.

    • PA is required when the initial step-therapy requirements are not satisfied.
    • Use the coverage criteria below to support the PA request.
    Step Therapy

    Initial Pharmacy Step Requirement

    First-line medications are covered without PA. A second-line medication will pay when the member has filled at least two different first-line medications or has filled a second-line medication within the past 180 days.

    • First-line options include generic Adderall XR, Concerta, Focalin XR, Metadate CD, and Ritalin LA.
    • Second-line options include generic Mydayis, Quillivant XR, Dyanavel XR, and Vyvanse (lisdexamfetamine) capsule.

    Policy Background

    This policy addresses stimulant pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD), with long-acting stimulant products organized into first-line and second-line tiers. First-line products are covered without prior authorization; second-line products generally require qualifying prior use or an approved clinical exception. A separate pathway applies to members whose coverage effective date is 90 days or less and who have documentation of current treatment with the requested drug. The policy also includes coverage for lisdexamfetamine capsules when prescribed for binge-eating disorder.

    Definitions

    Definition
    AbbreviationER
    MeaningExtended-release
    Policy contextUsed in long-acting stimulant product names

    Initial Therapy Requirements

    First-line therapy

    First-line medications are covered without prior authorization.

    First-line medication selection: Use one of the listed first-line medications: generic Adderall XR, generic Concerta, generic Focalin XR, generic Metadate CD, or generic Ritalin LA.

    Second-line point-of-sale requirement

    Second-line medications will pay when the member meets the qualifying prior-fill requirement.

    Qualifying prior fill: The member has filled at least two different first-line medications within the past 180 days, or has filled a second-line medication within the past 180 days.at least 2 different first-line medications or 1 second-line medication within 180 days

    If the requirement is not met, prior authorization is required.

    Step-Therapy Sequence

    StepRequirementCoverage outcome
    1Member must have filled at least two different first-line medications or a second-line medication within the past 180 days.Second-line medication pays automatically

    Drug and Dosage-Form Quantity Limits

    Quantity limit
    Drug and dosage formAmphetamine/dextroamphetamine ER capsule (generic Adderall XR), 5 mg, 10 mg, or 15 mg
    Quantity limit1 capsule
    FrequencyPer day
    Quantity limit
    Drug and dosage formAmphetamine/dextroamphetamine ER capsule (generic Adderall XR), 20 mg, 25 mg, or 30 mg
    Quantity limit2 capsules
    FrequencyPer day
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyAttention Deficit Hyperactivity Disorder (ADHD) Stimulants Step Therapy
    Policy CodePolicy N/A
    Change TypeMaterial update
    Effective DateJan 1, 202743d
    Last ReviewSep 9, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request when a second-line prescription does not meet the initial step-therapy requirement at the point of sale.
    SourceLink
    On This Page
    Coverage CriteriaProvider and Claim ActionsPolicy BackgroundDefinitionsInitial Therapy RequirementsStep-Therapy SequenceDrug and Dosage-Form Quantity Limits
    Prior Authorization

    Clinical Exception Pathway

    A second-line medication may be approved when the member has a qualifying clinical exception to the first-line step therapy or meets another listed coverage pathway. Document the applicable exception and submit a PA request when point-of-sale requirements are not met.

    • Trial and failure, an adverse reaction, or a contraindication to at least two first-line long-acting stimulants.
    • Trial and failure with at least one second-line long-acting stimulant.
    • For lisdexamfetamine capsule, diagnosis of binge-eating disorder.
    Documentation Required

    New-Plan Member Treatment Records

    For a member new to the plan, defined as a coverage effective date of 90 days or less, submit medical records documenting that the member is currently receiving treatment with the requested drug. This requirement does not apply when the product was obtained as samples or through a manufacturer’s patient assistance program.

    • Include treatment records supporting current use of the requested drug.
    • Do not rely on samples or manufacturer patient assistance program use as evidence of current treatment.
    Documentation Required

    Step-Therapy Exception Documentation

    For a step-therapy exception, submit documentation supporting the applicable pathway. Records should establish the relevant trial and failure, adverse reaction, contraindication, prior second-line trial and failure, or qualifying diagnosis.

    • Document trials and outcomes for at least two first-line long-acting stimulants when that pathway is used.
    • Document a trial and failure with at least one second-line long-acting stimulant when applicable.
    • For lisdexamfetamine capsule, document the diagnosis of binge-eating disorder.
    Denial Risk

    Failure to Meet Initial Step Therapy

    A second-line prescription will deny at the point of sale when the member has not met the initial step-therapy requirement. The claim will indicate that PA is required.

    • The member must have filled at least two different first-line medications or a second-line medication within the past 180 days.
    • Submit PA documentation rather than bypassing the pharmacy step requirement.
    Denial Risk

    Clinical Exception Criteria Not Met

    PA approval may be denied when the member does not satisfy a required coverage pathway or when supporting clinical documentation is insufficient. Approval requires the new-plan treatment record pathway or all applicable criteria for a qualifying clinical exception.

    • The clinical exception requires one qualifying criterion: failure, adverse reaction, or contraindication to at least two first-line long-acting stimulants; failure with at least one second-line long-acting stimulant; or lisdexamfetamine request with binge-eating disorder.
    • Approvals are granted for 12 months when criteria are met.
    Billing Rule

    Quantity Limit Exceeded

    Claims may deny or be adjusted when the prescribed quantity exceeds the product-specific quantity limit. Verify the daily dose and quantity limit before submitting the claim.

    • Adderall XR 5–15 mg: 1 capsule/day; Adderall XR 20–30 mg: 2 capsules/day; Mydayis: 1 capsule/day.
    • Focalin XR, Dyanavel XR tablet, Ritalin LA, Metadate CD, and Vyvanse: 1 unit/day; Dyanavel XR suspension: 8 mL/day; Quillivant XR: 12 mL/day.
    • Concerta 18, 27, and 54 mg: 1 tablet/day; Concerta 36 mg: 2 tablets/day.
    Quantity limit
    Drug and dosage formAmphetamine/dextroamphetamine 3-bead ER capsule (generic Mydayis)
    Quantity limit1 capsule
    FrequencyPer day
    Quantity limit
    Drug and dosage formDexmethylphenidate ER capsule (generic Focalin XR)
    Quantity limit1 capsule
    FrequencyPer day
    Quantity limit
    Drug and dosage formDyanavel XR (amphetamine ER) 2.5 mg/mL oral suspension
    Quantity limit8 mL
    FrequencyPer day
    Quantity limit
    Drug and dosage formDyanavel XR (amphetamine ER) tablet
    Quantity limit1 tablet
    FrequencyPer day
    Quantity limit
    Drug and dosage formMethylphenidate LA capsule (generic Ritalin LA)
    Quantity limit1 capsule
    FrequencyPer day
    Quantity limit
    Drug and dosage formMethylphenidate ER tablet (generic Concerta), 18 mg, 27 mg, or 54 mg
    Quantity limit1 tablet
    FrequencyPer day
    Quantity limit
    Drug and dosage formMethylphenidate ER tablet (generic Concerta), 36 mg
    Quantity limit2 tablets
    FrequencyPer day
    Quantity limit
    Drug and dosage formMethylphenidate ER (CD) capsule (generic Metadate CD)
    Quantity limit1 capsule
    FrequencyPer day
    Quantity limit
    Drug and dosage formQuillivant XR (methylphenidate) oral suspension
    Quantity limit12 mL
    FrequencyPer day
    Quantity limit
    Drug and dosage formLisdexamfetamine (Vyvanse) capsule
    Quantity limit1 capsule
    FrequencyPer day